Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Accumulated Expenses (2019 - 2025)

Immunocore Holdings (IMCR) has disclosed Accumulated Expenses for 7 consecutive years, with $219.7 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 18.44% to $219.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $219.7 million through Dec 2025, up 18.44% year-over-year, with the annual reading at $219.7 million for FY2025, 18.44% up from the prior year.
  • Accumulated Expenses hit $219.7 million in Q4 2025 for Immunocore Holdings, up from $144.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $219.7 million in Q4 2025 to a low of $36.9 million in Q4 2021.
  • Historically, Accumulated Expenses has averaged $140.2 million across 5 years, with a median of $143.8 million in 2025.
  • Biggest five-year swings in Accumulated Expenses: soared 98.29% in 2022 and later dropped 26.51% in 2025.
  • Year by year, Accumulated Expenses stood at $36.9 million in 2021, then skyrocketed by 98.29% to $73.2 million in 2022, then soared by 63.73% to $119.8 million in 2023, then skyrocketed by 54.82% to $185.5 million in 2024, then rose by 18.44% to $219.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for IMCR at $219.7 million in Q4 2025, $144.9 million in Q3 2025, and $143.8 million in Q2 2025.